143 related articles for article (PubMed ID: 33501754)
1. A recombinant influenza virus with a CTLA4-specific scFv inhibits tumor growth in a mouse model.
Lei GL; Wang LP; Dong SH; Sun F; Cheng JX; Yang XL; Zhang SG; Wang XL; Wang XX; Yang PH
Cell Biol Int; 2021 Jun; 45(6):1202-1210. PubMed ID: 33501754
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Efficacy of an Oncolytic Influenza Virus Carrying an Antibody Against Programmed Cell Death 1 in Hepatocellular Carcinoma.
Lei G; Li B; Yang H; Sun F; Li D; Yan J; Wang Y; Li R; Liu H; Zhang S; Li Y; Yang P
Hum Gene Ther; 2022 Mar; 33(5-6):309-317. PubMed ID: 35018832
[TBL] [Abstract][Full Text] [Related]
3. A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model.
Hamilton JR; Vijayakumar G; Palese P
Cell Rep; 2018 Jan; 22(1):1-7. PubMed ID: 29298413
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in Hepatocellular Carcinoma.
Yang H; Lei G; Sun F; Cheng J; Yan J; Zhang S; Yang P
Front Oncol; 2022; 12():875525. PubMed ID: 35494032
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
6. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Activity of a Novel Influenza A Virus Carrying Granulocyte-Macrophage Colony-Stimulating Factor in Hepatocellular Carcinoma.
Penghui Y; Fang S; Ruilan W; Guanglin L; Hongjing G; Yueqiang D; Zhongpeng Z; Xiaolan Y; Zhaohai W; Shaogeng Z; Xiliang W
Hum Gene Ther; 2019 Mar; 30(3):330-338. PubMed ID: 30205709
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
[TBL] [Abstract][Full Text] [Related]
9. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
10. A Recombinant Oncolytic Influenza Virus Carrying GV1001 Triggers an Antitumor Immune Response.
Li C; Tian Y; Sun F; Lei G; Cheng J; Tian C; Yu H; Deng Z; Lu S; Wang L; Xiao R; Bai C; Yang P
Hum Gene Ther; 2024 Jan; 35(1-2):48-58. PubMed ID: 37646399
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Immunotherapy.
Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
[TBL] [Abstract][Full Text] [Related]
12. A recombinant oncolytic influenza virus expressing a PD-L1 antibody induces CD8
Sun F; Xu Y; Deng Z; Yang P
Int Immunopharmacol; 2023 Jul; 120():110323. PubMed ID: 37207446
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
[TBL] [Abstract][Full Text] [Related]
14. An Engineered Influenza a Virus Expressing the Co-Stimulator OX40L as an Oncolytic Agent Against Hepatocellular Carcinoma.
Yang H; Lei G; Deng Z; Sun F; Tian Y; Cheng J; Yu H; Li C; Bai C; Zhang S; An G; Yang P
J Hepatocell Carcinoma; 2024; 11():1-13. PubMed ID: 38223555
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.
Kasloff SB; Pizzuto MS; Silic-Benussi M; Pavone S; Ciminale V; Capua I
J Virol; 2014 Aug; 88(16):9321-34. PubMed ID: 24899201
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
17. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
[TBL] [Abstract][Full Text] [Related]
18. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
Niemann J; Woller N; Brooks J; Fleischmann-Mundt B; Martin NT; Kloos A; Knocke S; Ernst AM; Manns MP; Kubicka S; Wirth TC; Gerardy-Schahn R; Kühnel F
Nat Commun; 2019 Jul; 10(1):3236. PubMed ID: 31324774
[TBL] [Abstract][Full Text] [Related]
19. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
Zamarin D; Holmgaard RB; Ricca J; Plitt T; Palese P; Sharma P; Merghoub T; Wolchok JD; Allison JP
Nat Commun; 2017 Feb; 8():14340. PubMed ID: 28194010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
